Início › Mieloma Múltiplo › Nova York

Ensaios clínicos de Mieloma Múltiplo em Nova York

75 estudos para Mieloma Múltiplo estão buscando participantes em locais em Nova York.

Cidades em Nova York

Texto oficial do estudo (Inglês)

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All protocol activities), New York
e mais 1

RecrutandoFase 2

Idades 60 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06679829

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site, Albany
Research Site, New York
Research Site, New York

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT07391657

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Icahn School of Medicine at Mt. Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05652335

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Memorial Sloan Kettering Cancer Center Mskcc, New York

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT04973605

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

New York Oncology Hematology, Albany
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
NYU Langone Health Manhattan, New York
e mais 1

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07518186

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Icahn School of Medicine at Mt. Sinai, New York
University of Rochester Medical Center, Rochester

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06500884

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Research Site, New York

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07073547

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Mount Sinai Brooklyn, Brooklyn
NYU Winthrop, Mineola
Mount Sinai Chelsea, New York
e mais 3

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07258511

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Mount Sinai Medical Center, New York
University of Rochester Medical Center, Rochester

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT04634552

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

Memorial Sloan Kettering, New York

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07336472

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07393282

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Hematology-Oncology Associates of CNY, East Syracuse
Northwell Health Cancer Institute, Lake Success
NYU Langone Hospital Long Island, Mineola
e mais 3

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05552222

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

MSK Commack, Commack
MSK Westchester, Harrison
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
e mais 2

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05623020

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Roswell Park Cancer Institute, Buffalo
Mount Sinai Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
e mais 1

RecrutandoFase 4

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT05201781

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Tisch Cancer Institute at Mount Sinai, New York
Memorial Sloan-Kettering Cancer Center, New York

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07116616

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Icahn School of Medicine at Mount Sinai /ID# 277844, New York
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946, New York
Weill Cornell Medicine Myeloma Center /ID# 278216, New York

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Northwell Health Monter Cancer Center, Lake Success
Northern Westchester Hospital, Mount Kisco
Cohen Children's Medical Center, New Hyde Park
e mais 4

RecrutandoFase 2

Idades 12 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT02693535

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

David H. Koch Center for Cancer Care, New York
Montefiore Medical Center PRIME, The Bronx

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT07648264

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Mount Sinai, The Tisch Cancer Instutute, New York

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT04879043

Collection of Tissue Samples for Cancer Research

Roswell Park Cancer Institute, Buffalo

RecrutandoEstudo observacional

2 Months · Todos os sexos · Atualizado em 16 de set. de 2026 · NCT00900198

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Weill Cornell Medical College, New York

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06615479

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Mount Sinai Hospital, New York
e mais 2

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06976476

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Roswell Park Cancer Institute, Buffalo
Icahn School of Medicine at Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214, New York

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06953960

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Icahn School of Medicine at Mount Sinai, New York

RecrutandoFase 2

Idades 70 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT06827860

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

New York Oncology Hematology, Albany

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT06980480

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute, New York

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 28 de ago. de 2026 · NCT06375044

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
North Shore University Hospital, Manhasset
Long Island Jewish Medical Center, New Hyde Park

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT06152575

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

MSK Commack, Commack
MSK Westchester, Harrison
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
e mais 2

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de ago. de 2026 · NCT05020236

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Research Site, New York

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT06106945

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

University of Rochester, Rochester
State University of New York Upstate Medical University, Syracuse
Upstate Cancer Center at Verona, Verona

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04566328

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Roswell Park Comprehensive Cancer Center, Buffalo

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06292780

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Roswell Park Cancer Institute, Buffalo

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT06627751

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Memorial Sloan-Kettering Cancer Center, New York

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, Buffalo
Research Site, New York
Research Site, Stony Brook

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT05850234

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
e mais 1

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 17 de ago. de 2026 · NCT07105059

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Albany
Research Site, New Hyde Park
Research Site, New York
e mais 3

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT07764978

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Comprehensive Cancer Center, Buffalo

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 13 de ago. de 2026 · NCT06622005

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Perlmutter Cancer Center at NYU Langone Hospital, Brooklyn
Memorial Sloan Kettering Cancer Center, New York

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT07280013

Delayed Toxicities Post-CAR-T

Mount Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT07665307

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.